Megexia (Megestrol Acetate)

Megestrol acetate binds to progesterone receptors and also displays glucocorticoid activity. This dual action modulates gene transcription that increases appetite, reduces catabolic processes, and exerts anti‑estrogenic effects that help control hormone‑sensitive tumors.

The dose of Megexia is individualized by the prescribing clinician based on the specific indication, patient weight, clinical response, and tolerance. No fixed regimen is provided here; the prescriber sets the appropriate dosage.

Safety data for megestrol acetate in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk. Consultation with a healthcare professional is essential.

To request Megexia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other appetite stimulants such as dronabinol or mirtazapine, Megexia (megestrol acetate) offers both appetite‑enhancing and antineoplastic properties, making it particularly useful in cancer‑related cachexia. Its progestogenic profile may lead to different side‑effect patterns, such as hormonal changes, which should be considered when selecting therapy.

Megexia tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Megexia is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact administration schedule, including timing and whether it should be taken with meals, is determined by the treating clinician.

Serious risks include thromboembolic events, adrenal suppression, severe allergic reactions, hyperglycemia that may precipitate diabetes, and Cushing‑like syndrome. Patients should be monitored closely for signs of these conditions, especially during long‑term therapy.

Megexia should be avoided in patients with known hypersensitivity to megestrol acetate, active thromboembolic disease, uncontrolled diabetes, severe infection, or those receiving concurrent strong CYP3A4 inhibitors without appropriate monitoring. Pregnant or nursing women should only use it if clearly indicated by a physician.